Denise Myshko

Healthcare journalist Ken Terry’s new book proposes a subscription-based primary care system as a free-market alternative to Medicare for All.

Robyn S. Crosson, J.D., VP of government relations at Navitus Health Solutions, has won the PBMI Innovators Award for her work advancing transparency in pharmacy benefits.

Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.

Awiqli is the first once-weekly basal insulin for Type 2 diabetes. It has a list price of $99 a package and is also available for a $35 copay for eligible patients.

The phase 3 trial will evaluate the efficacy of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in metabolic dysfunction-associated steatohepatitis patients with moderate to advanced fibrosis, using an AI tool to standardize liver biopsy assessment.

New research in Menopause shows diabetic women face greater symptom burden during menopause transition, suggesting diabetes care should incorporate menopause symptom assessment and management.

In June, the FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 in favor of Moderna’s mFlusiva, saying the benefits outweigh its risks for the prevention of influenza in adults older than 50.

A study by the American Diabetes Association also finds that 1.5 million diabetic Medicaid enrollees face new cost-sharing by 2029, potentially adding $1,000 in annual out-of-pocket costs in some states.

Tufts researcher James Chambers, Ph.D., says IRA’s Medicare price negotiation program should target drugs that are unlikely to face biosimilar competition.

A mouse study found that formoterol was able to reduce liver fat, and a real-world analysis found that the asthma drug was associated with fewer complications from advanced liver disease and lower rates of several serious liver-related outcomes, including cirrhosis and all-cause mortality.

In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, discusses how biosimilars have improved access to biologics, but more work needs to be done for patients to see cost reductions.

Yesafili joins Amgen's Pavblu as a competing Eylea biosimilar.

Gleason considered going into the family mortuary business. In his decades at Prime Therapeutics, he has become one of the most respected people in the pharmacy benefit management industry. Next year, as the president of the Academy of Managed Care Pharmacy, he wants to combat misinformation about vaccines.

From her perch at Navitus, Crosson has become a prominent advocate on PBM transparency and prescription drug affordability issues, frequently speaking with policymakers, industry groups, and healthcare stakeholders about legislative reforms and regulatory trends.

Like Journavx, LTG-001 is a Nav1.8 inhibitor that is designed to selectively block the transmission of pain without the risk of addiction.

Children using virtual reality needed significantly lower nitrous oxide concentrations during Botox procedures, potentially reducing side effects like nausea, vomiting, and hallucinations, researchers reported.

Specialty drug spend is being driven by utilization, while the non-specialty trend is being pushed up as a result of the use of GLP-1s for diabetes and for weight loss.

Data presented at the International AIDS Conference 2026 show Cabenuva reduced viral rebound in adolescents versus oral therapy, but access to long-acting injectables remains limited where need is greatest, investigators said.

In the VOGUE trial, Dovato matched Biktarvy at week 48, demonstrating that it was noninferior in HIV-1 viral suppression in treatment-naive adults, including high-risk patients.

The approval of centanafadine, now with the brand name, Simtriyo, introduces a new treatment approach for adults and children with ADHD.

Once-weekly zabopegdutide produced weight loss, better glycemic control, and favorable liver enzyme changes in a 67-patient phase 2 trial of patients with MASH.

Industry leaders Tom Kraus and Shawn Gremminger debated 340B’s value during a Managed Healthcare Executive/Drug Topics webinar. Panelists clashed over transparency, safety-net eligibility, and how 340B savings should be spent.

A survey by Spherix Global Insights also finds that health plans and pharmacy benefit managers are using Medicare’s Maximum Fair Prices as benchmarks when negotiating discounts for drugs that were not selected for price negotiations.

Already approved for familial chylomicronemia syndrome, Redemplo now shows efficacy in severe hypertriglyceridemia; Arrowhead plans a U.S. sNDA filing before year-end.

An analysis at Montefiore Medical Center in New York finds that expanding CGM implementation in primary care improves diabetes outcomes and reduce acute care utilization, particularly in underserved populations.

Despite similar diabetes technology use among the minority patients surveyed, Black patients showed higher A1C than White non-Hispanic patients, with insurance access and cost as the biggest barriers to using insulin pumps or connected insulin pens.

A mathematical model of one clinic found that step therapy for Vabysmo in patients with diabetic macular edema would cost $380,000 annually and add more than 8,000 staff hours.

Two presentations found that the loss of Good Days copay assistance forced retina patients onto bevacizumab, worsening anatomic outcomes and visual acuity despite more frequent dosing. Researchers said this highlights the importance of copay assistance in maintaining disease stability.

Vabysmo reduced injection burden in both untreated and previously treated patients without impacting vision or retinal thickness in a two-year real-world analysis.

A real-world analysis of nearly 2,700 eyes with diabetic macular edema found about 30% of Eylea HD patients reached 12-week or longer dosing intervals, reducing treatment burden over time.